NASDAQ · MIRM
Mirum Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MIRM: Nov 03, 2026
Mirum Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/03/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.53. The reported EPS for the same quarter last year was $0.05.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.53 | $0.05 | $-0.87 | 5 |
| Dec 2026 | $-0.58 | $-0.11 | $-1.17 | 6 |
| Mar 2027 | $-0.17 | $0.07 | $-0.41 | 2 |
| Jun 2027 | $-0.16 | $0.12 | $-0.43 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat- Zacks · Oct 28, 9:00 AM EDTRecursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseRecursion Pharmaceuticals (RXRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 9:00 AM EDTMirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseMirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 26, 10:18 AM EDTMirum's ATEBRIOZ Reduces Bone Lesion Volume In Younger Children With FOP; Stock Up(RTTNews) – Mirum Pharmaceuticals (MIRM) reported positive results from Cohort 2 of the pivotal PROGRESS study evaluating ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to under 12 years with fibrodysplasia ossificans progressiva (FOP).
- RTTNews · Oct 26, 9:54 AM EDTMirum Reports Positive ATEBRIOZ Results In Younger Children With FOP(RTTNews) – Mirum Pharmaceuticals (MIRM) reported positive Cohort 2 results from the Phase 2 PROGRESS study of ATEBRIOZ (zilurgisertib) in children aged 6 to under 12 years with fibrodysplasia ossificans progressiva (FOP).
- RTTNews · Oct 16, 3:02 PM EDTFDA Drug Approvals In September 2026(RTTNews) – The U.S. Food and Drug Administration (FDA) approved 13 drugs in September 2026, spanning first-in-class therapies, treatments for rare diseases, and new options for patients with serious conditions.With the month yielding a mix of new therapies and expanded treatment
- RTTNews · Oct 16, 10:55 AM EDTWeekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) – This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.
- Zacks · Oct 13, 9:41 AM EDTMirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver DiseasesMIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
- MarketBeat · Oct 12, 11:02 AM EDTMirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver DiseasesMirum Pharma: A Rare Disease Growth Story to WatchMirum Pharmaceuticals (NASDAQ:MIRM) said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associated with ult
- RTTNews · Oct 12, 9:16 AM EDTMirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results; Plans FDA Filing In 2027(RTTNews) – Mirum Pharmaceuticals, Inc. (MIRM), a rare disease-focused biopharmaceutical company, announced positive topline results from the Phase 3 EXPAND study of LIVMARLI (maralixibat) in patients with ultra-rare cholestatic liver diseases. The study met its primary endpoint,
- RTTNews · Oct 12, 9:08 AM EDTMirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study(RTTNews) – Mirum Pharmaceuticals (MIRM) announced positive topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for cholestatic pruritus in patients aged six months and older with ultra-rare cholestatic liver diseases, including biliary atresia.
- MarketBeat · Oct 2, 3:02 PM EDTMirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta StudyMirum Pharma: A Rare Disease Growth Story to WatchMirum Pharmaceuticals (NASDAQ:MIRM) reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint
- RTTNews · Oct 2, 12:13 PM EDTWeekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data(RTTNews) – The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic deals and corporate activity. Key updates spanned oncology, rare diseases, cardiov
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Mirum Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.